viernes, 28 de noviembre de 2014

Ratón de biblioteca: S.I.D.A. ¿Maldición bíblica o enfermedad letal? / A.Cardin & A. de Fluvia (Editores)

'We saw our first AIDS patient in July 1980. 
He was a 33-year-old homosexual, 
originally from West Germany, 
who had lived for the past three years in Haiti, 
where he'd worked as a chef," 

Dr. Donna Mildvan*, chief of infectious diseases 
Beth Israel Medical Center

"A pesar de la intermitente alarma de los periodicos y del miedo que recorre a las comunidades de otros paises, el SIDA sigue siendo contemplado en España con indiferencia cuando no con audaz menosprecio.
Bien es verdad que la incidencia de dicha enfermedad ni alcanza aún cifras alarmantes pero también es cierto que van sumados ya 18 casos y ni se han tomado aún medidas preventivas, ni se han establecido centros de control y análisis de datos, ni resulta siquiera posible localizar equipos o dispensarios donde se atiendan, informen y evaluen los casos sospechosos."

Son reflexiones (premonitorias?) que, en contraportada, Alberto Cardín (Villamayor, Asturias 15.1.1948 / Barcelona 26.1.1992), como editor, coloca en esta recopilacón de textos facilitados por Armand Fluviá (archivador de material "gay"). Corria 1985...

Cinco años atrás (1980), Donna Mildvan* (amiga en Venezuela y NyNy) ya reportaba su primer caso, un varón homosexual de 33 años.

Dos después (1982), ella en Nueva York / yo en California, Donna me advertía del riesgo. El AIDS/SIDA había dejado de ser una enfermedad de "gays". Habían diagnosticado también la enfermedad en niños, mujeres y hombres heterosexuales...

En los 80´s las farmacias españolas, de manera irresponsable, negaban la venta de inyectadoras a quien no viniera con receta médica...

Años más, siete, vivió Alberto Cardín

"El Sida lo mató, aunque al sobrevenirle el mal ni se replegó ni abandonó el estudio y sus múltiples ocupaciones, todo lo contrario, se convirtió en uno de los más destacados investigadores del fenómeno, que divulgó en artículos y libros como 'Sida, ¿maldición bíblica o enfermedad letal?' (1985), escrito en colaboración con Armand de Fluviá, o 'El estigma en la sombra, la atípica marginalidad de los homosexuales portadores de sida' (1989), o en el prólogo que le puso, en 1991, a 'Sida, enfoques alternativos', que quería ser, como dijo, «una propuesta informativa sobre posibilidades reales de terapias alternativas», a fin de que se hiciera una «gestión responsable de la enfermedad por parte de aquellos que la padecen». (Más)


Años menos, veinticinco, con Alberto Cardín coincidía muchas veces en el tren de carbón (Ferrocarriles Económicos de Asturias), él en Villamayor/yo en Arriondas, camino de Gijón, al Colegio de la Inmaculada (PPJesuitas) donde estudiábamos.En pocos días celebraré allá las "bodas de oro" de mi promoción. En la del año próximo (la suya) el no estará...
 
(*) Donna Mildvan, chief of Infectious Disease at Beth Israel Hospital on Manhattan's Lower East Side, had been studying sexually transmitted intestinal infections in gay men since the mid-1970s. Her initial interest in the subject was piqued by an unusual, puzzling case of protozoal infection, "unheard of" in a patient with no travel history. She and her colleague Dan William, a gay physician working on sexually transmitted diseases at New York City's Department of Health, assembled a cohort of sexually active gay men to study enteric diseases. 

In the late 1970s, Mildvan noticed lymphadenopathy or swollen lymph glands in a number of them. Neither she nor other doctors she consulted could make a diagnosis. Lymph node biopsies came back negative. Here was another medical mystery, one that Mildvan set aside for want of sufficient data. In 1980, an event occurred that only heightened her perplexity.(Más)

Act Up: VIH Empoderamiento ciudadano






 


jueves, 27 de noviembre de 2014

The Access to medicine Index 2014

"...al fin de cuentas, 
las empresas farmacéuticas no se dedican 
a la actividad empresarial 
empujadas por la bondad dentro de sus corazones, 
y no hay dinero que ganar en la prevención 
y curación de las enfermedades de los pobres." 

Joseph E. Stiglitz, Univ.de Columbia 
Premio Nobel de Economía 2001
 
The Access to Medicine Index (descargar) independently ranks pharmaceutical companies’ efforts to improve access to medicine in developing countries. Funded by the Bill & Melinda Gates Foundation and the UK and Dutch governments, the Index has been published every two years since 2008.

Ver:

 The Access to Medicine Index 2010

 The Access to Medicine Index 2012


The access to medicine problem is multifaceted, and responsibility for tackling it lies with many different actors - governments, NGOs, academia, pharmaceutical companies, finance institutions and multilateral organisations such as the WHO. As manufacturers and developers of life-saving products, pharmaceutical companies clearly have a crucial role to play.


 Click sobre imagen para ampliar

Why an Index? 

The Index publicly recognises companies for their investments in access to medicine, raising awareness of relevant issues within pharmaceutical companies and providing them with a transparent means by which they can assess, monitor and improve their own performance as well as their public and investment profiles. Consistent iterations of the Index highlight industry trends and provide a basis for multi-stakeholder dialogue and solution building.


Five companies are developing more than half of the products in the pipeline for developing countries.

The top 20 pharmaceutical companies are developing 327 relevant products, with only five companies (Novartis, J&J, GSK, AbbVie and Sanofi) accounting for more than half the pipeline and more than half the products targeting only five diseases. 


Compared to 2012, pricing strategies are increasingly tailored, as more companies take account of socioeconomic factors, such as ability to pay. Importantly, more companies are setting different prices for different segments of national populations.

How Much Does it Cost to Develop a Drug? What do you Think? / Ed Silverman en TWSJ

For years, there has been intense debate over what it costs to develop a new drug. And tomorrow, one think tank hopes to put the issue to rest. Of course, this remains to be seen. 

Drug makers maintain the true cost should reflect the investment in not only the hits, but the misses. In other words, the pharmaceutical industry says the expense needed to successfully concoct any one medicine should incorporate the costs of the many failures that occur along the way. 

Conversely, consumer advocates and some academics, among others, regularly contest industry estimates, which have been rising over the years. As they see it, the numbers proffered by drug makers mask a combination of irrelevant and overstated expenses. And these estimates, they go on to argue, are unfairly used to justify rising prices. 

For these reasons, arguments are likely to continue. Nonetheless, the Tufts Center for the Study of Drug Development on Tuesday will release a report that will take yet another stab at determining the true cost. The last time the think tank offered an estimate was in 2003, when it calculated the cost to develop a drug at $802 million. The findings were published in the Journal of Health Economics.

Ver:

FORBES: El "sorprendente" costo de la invención de nuevos medicamentos.


So what might the latest number from Tufts look like? Already, the betting has begun. A forum run by one consumer advocacy group is asking participants to guess and, so far, their answers have ranged from about $1.1 billion to $2.5 billion

Since 2003, various estimates have suggested the cost has increased significantly. Two years ago, for instance, the cost was estimated at $1.5 billion by the Office of Health Economics, a consulting firm that received an unrestricted grant from AstraZeneca to compile its report. The Tufts analysis, however, remains widely cited as a benchmark. How does the Tufts Center calculate the cost? The non-profit think tank relies on data supplied, in part, by the pharmaceutical industry as well as other sources. For those who are interested, the methodology will be released along with the bottom-line calculations. We should note, by the way, that the Tufts Center is funded, in part, by the pharmaceutical industry

So what do you think the number will be? No, there is no prize for the person who guesses correctly, but this is as good a time as any to think it over.n (Ver)

Ver también:

Desmitificando el costo de desarrollo de un nuevo medicamento.

miércoles, 26 de noviembre de 2014

The next pharma Blockbusters...Merck, BMS, AstraZeneca, Roche.


  
Ver 
y descargar informe


In September, Merck's PD-1 blocker Keytruda (pembrolizumab) received accelerated approval from the FDA to treat melanoma and the company is researching the drug against non-small cell lung cancer (NSCLC) and other indications. In its World Preview 2014 Outlook report, EvaluatePharma forecasts Keytruda sales of $4.06 billion by 2020.

That's a great start, but it's unclear whether Merck's advantage will hold out over the long haul. The competition will be fierce in the PD-1/PD-L1 space. With the huge potential market, this could be the equivalent of the Oklahoma land rush for the usual pharma titans. However, Stephanie Hawthorne, senior director at Kantar Health, notes that, for now in melanoma, Merck is in the driver's seat compared to BMS's PD-1 inhibitor Opdivo (nivolumab), which is a few months (or possibly longer) behind Keytruda in the US. 

"It's a big advantage for Merck being first-to-market," says Hawthorne. "Based on the available data, they both look really efficacious, and they're fairly well tolerated compared to Yervoy. BMS's saving grace might be the combination of Opdivo and Yervoy they are studying. The survival data we've seen for it so far is really impressive, and that could trump Merck's lead." 

Hawthorne's point was underscored in late September when BMS released data at the European Society for Medical Oncology (ESMO) showing that Opdivo achieved a 32% response rate against advanced melanoma in patients who had previously been treated with Yervoy. The control group, which received traditional chemo, had an 11 % response. 

While Keytruda was first in the US, Opdivo was approved for melanoma in Japan in July, under a deal with BMS partner Ono Pharmaceuticals. The ESMO data will only support BMS's showing in the US. The FDA has given Opdivo fast track designation in NSCLC, melanoma, and renal cell carcinoma (RCC) and breakthrough therapy designation for Hodgkin's lymphoma. In September, BMS announced that both the FDA and European Medicines Agency (EMA) have accepted Opdivo for accelerated review for melanoma. The FDA PDUFA date is March 30, 2015. 

"Opdivo is the most valuable pipeline drug in development at the moment," says Lisa Urquhart, editor of Evaluate's editorial team, EP Vantage. "The data from studies is showing some impressive advances in both overall survival and disease progression." 

EvaluatePharma pegs Opdivo's potential sales at $6 billion by 2020. The company believes Opdivo could be approved for melanoma in the US next year. Meanwhile, Hawthorne expects approval for the Opdivo/Yervoy combination in early 2016. 

That's in melanoma. Opdivo may even have a more clear-cut advantage in being first-to-market for NSCLC, where BMS has already submitted its drug for approval while Merck is still completing Phase III trials. 


 Genentech/Roche's PD-L1 offering, MPDL3280A (RG-7446), is in trials for NSCLC, melanoma, RCC, and bladder cancer. The company received breakthrough designation for this last indication. EvaluatePharma puts sales at $2.93 billion by 2020, while the Thomson Reuters Cortellis database puts them at $1.2 billion by 2019. 

MedImmune/AstraZeneca is also in the race with PD-L1 drug MEDI-4736, primarily targeting NSCLC. Also shared at ESMO, a small 18-person study showed a 28% response to MEDI-4736 combined with the CTLA-4-directed antibody tremelimumab. Cortellis projects MEDI-4736 sales at close to $1.1 billion by 2019. 

"We're just at the tip of the iceberg for immuno-oncology, but the enthusiasm is certainly warranted because of the kinds of responses and the tumors being opened up," says Fernandez. "The field is about as exciting and confusing as you could possibly imagine." (Más)

Anish Shindore* se "en red_a" con NOVARTIS/ "The competition is still in the product, not the social media page."


"The Spanish people are very passionate and outspoken; they want to express their opinions," Anish explains pragmatically, 

"They a very good country when it comes to using a medium that is already out there. However, starting a new medium is not something for which they are well known. Adaptation is very fast, but uptake is very slow. For example Facebook really only gained momentum 3-4 years ago in Spain, yet now seemingly everyone is using it.

"Novartis aspires to be the most innovative pharmaceutical company. But that is not really about 'digital' or 'social media'. R&D in medicines has to be our focus, not by innovating with some shiny new mobile app. Innovation is part of our culture, but it has to start with having good drugs. My role is to help us adapt to what the market is doing and add the possibility of interaction with customers." 

"For us and others, we are still getting too excited with social. Sure, it is the present aspect of interest, however history shows there will be equally be an opposing 'anti-social' movement in the next few years. We should ensure we do not get too far away from our core business; that is, what we do best."


Ver:

Social media in Spain; core to pharmaceutical innovation? / Paul Grant


  (*) Anis Shindore eMarketing / Digital Commercialization Head for Novartis in Spain

martes, 25 de noviembre de 2014

I Estudio de reputación en Esalud de la Industria Farmacéutica 2014

...el presente documento pretende analizar la evolución de la relación a través de la eSalud de los laboratorios farmacéuticos con su entorno. Para ello se ha realizado un estudio comparativo entre las distintas empresas farmacéuticas que operan dentro del ámbito nacional obteniendo datos estadísticos que evalúan el estado actual de grado de penetración de soluciones de aplicación de las TIC en el sector. De dicho estudio se obtienen unas conclusiones y se esboza el futuro que se prevé en base a las tendencias del mercado. También se compara el uso de la eSalud en otros actores del sector sanitario, para poder valorar el grado de madurez de las soluciones en la industria farmacéutica.





En general podemos concluir que el sector farmacéutico está usando en muy poca medida las nuevas posibilidades que este campo ofrece para potenciar negocio o actividades relacionadas. Si bien ha habido una inmersión en lo que podemos llamar la Web 1.0, es decir, la presencia de los laboratorios en Internet es algo completamente asumido y normal, no ha habido una evolución posterior llamativa. Encontramos grandes contrastes entre las páginas Web analizadas, desde las más punteras y actualizadas hasta muchas que necesitan dar un salto hacia las posibilidades actuales. Lo mismo ocurre con las páginas desarrolladas para colectivos específicos, médicos, farmacéuticos, pacientes o investigadores: se han centrado en la gestión de contenidos y no han evolucionado, en la mayoría de los casos, al siguiente nivel. Los contrastes de calidad son también acusados.(Más/Descargar)

Top 10 Pharma Companies using Social Media / IMS Healtt Social Media Report


Based on the IMS Health Social Media Report which is released by the beginning of 2014 , Among the top 50 pharmaceutical companies, half do not engage with consumers or patients through social media on healthcare-related topics. 

IMS Health ranked the top 10 Pharmaceutical companies on using Social Media as follow :

  1. Johnson & Johnson 
  2. GlaxoSmithkline 
  3. Novo Nordisk 
  4. Pfizer 
  5. Novartis 
  6. Boehringer Ingelheim 
  7. Bayer 
  8. Merck & Co 
  9. AstraZeneca
  10. UCB



IMS Health used several indices to rank those companies like :

  • Reach index : which is the measure of the absolute number of listeners and the index is based on the number of people reached by each channel through likes, shares and re-tweets. 

  • Relevance Index : Which is the measures whether people found posts or content relevant and/or useful, and the index is based on the extent to which content is being shared and forwarded across social networks.

  • Relationship Index : A measure of interaction - the back and forth of conversation - and a measure of company and consumer or patient integration. f

    The relationship index measures the level of interaction between a company and those who post, reply or otherwise interact with the company’s postings.
  • Johnson & Johnson is the most social Pharma company in the world followed by GlaxoSmithKline and Pfizer
  • Johnson & Johnson is the most mentioned brand on social media. 
  • Bayer has the most active and the highest fan base on Facebook. As a result Bayer is ranked no. 1 on Facebook among all competitors. 
  • Pfizer scored the highest on Twitter.
Más

lunes, 24 de noviembre de 2014

Humor:..es lunes: #Sanichollo/Salud "low cost"...



Creatividad Sir Richards condoms : “Have sex, save lives.”




I’m doing my part to help the world. That’s what we do here at Sir Richard’s. For every condom you purchase, we donate one to a developing country. So far, Sir Richard’s has donated over 2.5 million condoms.

Buy One, Give One Sir Richard’s Impact Sir Richard's was founded in 2009 by a team of socially conscious entrepreneurs and designers. Sir Richard’s condoms were launched in the market in January 2011. The company’s founders believed that the time was ripe to breathe life into a very dated product category controlled by one or two companies that hadn’t innovated in decades. 

At the core of their purpose, the founders also wanted to connect product sales and company growth with a direct global humanitarian impact. As such, since its founding, for every condom Sir Richard’s sells, we donate one condom to a community in need. To date, we have donated millions of condoms as part of our Buy One, Give One program. 

Over our first few years, Sir Richard’s primarily partnered with Partners In Health as a distribution partner to get condoms safely and effectively to Haiti. These condoms have been made available at no charge through PIH's clinics. 


Partners In Health ranks as one of the largest nongovernmental health care providers in Haiti with over 5,000 employees and more than 2.6 million patient visits at its clinics in 2008. It launched the world's first program to provide free, comprehensive HIV care and treatment in an impoverished setting, and as part of its prevention efforts distributes (on average) two million condoms per year. 

In early 2014, the company initiated its “Nominate a Cause” program to crowdsource Buy One, Give One donation recipients. Sir Richard’s customers can now nominate a cause they care about to receive donated condoms.(Más)


domingo, 23 de noviembre de 2014

"Grita contra el VIH" con Jansen y Control...



Esta aplicación impulsará el evento Grita contra el VIH que se celebrará en noviembre en Madrid, Barcelona, Valencia y Málaga.


El 30 % de los nuevos diagnósticos de VIH en España pertenecen a jóvenes menores de 29 años, según el informe de Vigilancia epidemiológica del VIH y sida en España de 2013 del Ministerio de Sanidad. La Coordinadora estatal de VIH y sida – CESIDA, desde su proyecto HIV Think Tank destinado a jóvenes del ámbito universitario ha presentado una aplicación móvil para facilitarles el acceso a la información del VIH. 

 Grita contra el VIH 

 La aplicación también llama a la participación activa y simbólica a través del grito. “Un grito que representa de manera metafórica el inconformismo de la juventud frente a la propagación del VIH”, afirma Juan Ramón Barrios, presidente de CESIDA. 

 Esta acción se enmarca dentro de ‘Noise against AIDS’, proyecto ganador de la primera edición del HIV Think Tank, un programa desarrollado por CESIDA y JANSSEN y catorce entidades de CESIDA. 

A la convocatoria se presentaron 62 proyectos elaborados por casi 200 estudiantes de más de 65 universidades de toda España. 

 Esta app contiene datos geolocalizados de dónde recoger preservativos gratis, gracias a la colaboración de CONTROL, así como un listado de entidades de CESIDA donde hacerse la prueba del VIH de forma rápida, gratuita y confidencial. 

 La aplicación móvil, HIVTT, se puede descargar desde las siguientes direcciones:

– Apple: http://gritovih.es/hivttios 
– Android: http://gritovih.es/hivandroid

sábado, 22 de noviembre de 2014

TAMARANG Pharmaceuticals: Tanta culpa tiene el que mata como...


Si EE UU vive un problema de desabastecimento de un producto que es básico para la supervivencia de su seña de identidad más repulsiva y arcaica (la pena capital en vigor) cabría preguntarse por qué sus empresas no fabrican tales productos.¿Cómo es posible que EEUU no pueda producir pentotal, la anestesia necesaria para dormir a un preso antes de que otro fármaco le paralice los músculos y luego otro le provoque un paro cardíaco que le conduzca a la muerte dictada? Beneficios. Esa es la respuesta. 

Cuando un fármaco carece de patente, automáticamente se le adhiere la etiqueta de no rentable, por lo que su fabricación no es atractiva —en términos monetarios— para las grandes compañías.
Cuando en 2010 Hospira tuvo problemas para continuar fabricando en Italia el pentotal debido a que la opinión pública italiana forzó a la compañía a entablar un diálogo con las autoridades de aquel país sobre su uso y su final, se puso de manifiesto que no había muchas opciones, excepto importar de otras empresas europeas o recurrir a soluciones intermedias, como usar pentobarbital, un sedativo utilizado para sacrificar perros y gatos, principalmente. Oklahoma ya lo había utilizado en los años setenta, por lo que no había razón para no seguir una senda ya conocida.

Ver:
Ironias de la muerte... (cont.)

Cierto es que la exportación del fármaco por parte de Tamarang no incumple ninguna normativa —el principio activo no está incluido en el reglamento 1352/2011 de la Unión Europea, que prohíbe la exportación de materiales y sustancias que puedan ser utilizadas en torturas y ejecuciones—, pero en su batalla contra la pena de muerte en todo el mundo, Reprieve presiona para que medicinas de uso hospitalario no acaben quitando la vida a alguien. 

Tamarang es una pequeña empresa de apenas cuatro trabajadores situada en la calle de Balmes de Barcelona que tiene como “actividad principal la elaboración de registros farmacéuticos y la comercialización de específicos”, según consta en las cuentas depositadas en el Registro Mercantil correspondientes al ejercicio de 2012, el último disponible. La empresa, que no tiene fábrica propia, está asociada con Farmhispania, un gigante del sector farmacéutico español —factura más de 60 millones de euros anuales—, que sí fabrica este principio activo. 

Una empleada de la compañía confirma la venta de "millones de viales" a Estados Unidos 

Una empleada de Tamarang confirmó a EL PAÍS que la compañía exportó el año pasado “millones” de viales de rocuronio bromuro a EE UU, aunque matizó que la compañía “no los vende directamente” en ese país, sino que los sirve al laboratorio estadounidense X-GEN, que los comercializa bajo su propia marca. “Es un producto utilizado en muchos hospitales y no tenemos el control del destino final del producto”, admitió. 
En opinión de Reprieve, de eso se trata, de saber cuál es el destino final e impedir que los fármacos acaben en los corredores de la muerte, para lo que es necesario que las empresas asuman un protocol interno de responsabilidad. De otro modo, se convierten en cómplices. 

La trabajadora de Tamarang confirmó la recepción de una carta de Reprieve el pasado octubre. “Lo tomamos como un tema grave y peliagudo y lo trasladamos a los dueños de la empresa, que lo están estudiando”. Este diario solictó, sin éxito, hablar con los máximos responsables de la compañía. (Más)

Ver también:

USA: "Muerte" a Propofol, droga de la "pena de muerte"...